| Pulmonary embolism COVID-19 patients (n = 1117) | Non-pulmonary embolism COVID-19 patients (n = 30,383) | Odds ratio, p value |
---|---|---|---|
Age ± SD | 62 ±  (15.1) | 57 ±  (19.7) | 1.014 (1.011–1.018), p < 0.001 |
Females | 474 (42%) | 15,180 (49%) | 0.73 (0.65–0.83), p < 0.001 |
Race | Â | Â | Â |
 Caucasians | 555 (49%) | 15,513 (51%) | 0.94 (0.84–1.06), p = 0.36 |
 African American | 378 (33%) | 8361 (27.5%) | 1.34 (1.18–1.52), p < 0.001 |
 Asian American | 38 (3.4%) | 719 (2.3%) | 1.45 (1.04–2.2), p = 0.02 |
 Others | 168 (15%) | 5790 (19%) | 0.75 (0.63–0.88), p < 0.001 |
Atrial fibrillation/flutter | 168 (15%) | 3685 (12.1%) | 1.28 (1.08–1.51), p = 0.003 |
HTN | 677 (60.6%) | 15,817 (52%) | 1.41 (1.25–1.60), p < 0.001 |
Diabetes | 393 (35.1%) | 8317 (27.3%) | 1.44 (1.27–1.63), p < 0.001 |
Atherosclerosis | 171 (15.3%) | 4350 (14.3%) | 1.08 (0.91–1.27), p = 0.35 |
Acute kidney injury | 472 (42.2%) | 8459 (27.8%) | 1.89 (1.67–2.14), p < 0.001 |
Chronic kidney disease | 156 (13.9%) | 3588 (11.8%) | 1.21 (1.02–1.44), p = 0.02 |
Congestive heart failure | 234 (20.9%) | 5085 (16.7%) | 1.31 (1.13–1.52), p < 0.001 |
Chronic obstructive pulmonary disease | 116 (10.3%) | 3098 (10.19%) | 1.02 (0.83–1.24), p = 0.83 |
Obstructive sleep apnea | 178 (15.9%) | 3922 (12.9%) | 1.27 (1.08–1.50), p = 0.003 |
Sepsis | 386 (34.5%) | 6742 (22.1%) | 1.85 (1.63–2.1), p < 0.001 |
Hypothyroidism | 148 (13.2%) | 3601 (11.8%) | 1.13 (0.95–141), p = 0.15 |
Obesity | 339 (30.3%) | 7251 (23.8%) | 1.39 (1.22–1.58), p < 0.001 |
Malignancy | 68 (6%) | 766 (2.5%) | 2.5 (1.94–3.23), p < 0.001 |
Anemia | 366 (32.7%) | 7106 (23.3%) | 1.59 (1.40–1.81), p < 0.001 |
Nicotine dependence | 107 (9.5%) | 3118 (10.2%) | 0.92 (0.75–1.13), p = 0.45 |
Acute DVT of extremities | 102 (9%) | 66 (0.2%) | 46.16 (33.65–63.3), p < 0.001 |
Acute encephalopathy | 125 (11.2%) | 1819 (6%) | 1.98 (1.63–2.39), p < 0.001 |
Stroke/cerebrovascular diseases | 65 (5.8%) | 1077 (3.5%) | 1.66 (1.28–2.18), p < 0.001 |
Steroids | 610 (54%) | 11,653 (38.3%) | 1.93 (1.71–2.18), p < 0.001 |
Remdesivir | 311 (27%) | 5746 (18.9%) | 1.65 (1.45–1.89), p < 0.001 |
Tocilizumab | 32 (2%) | 410 (1.3%) | 2.15 (1.49–3.10), p < 0.001 |
Hydroxychloroquine | 86 (7.6%) | 2020 (6.6%) | 1.17 (0.93–1.46), p = 0.17 |